ERENDOR, F. Et Al. 2019. LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes. ESGCT 27th Annual Congress in collaboration with SETGyc , (Barcelona, Spain), 1.

ERENDOR, F., ŞAHİN, E. Ö., BALCI, M. K., & ŞANLIOĞLU, S., (2019). LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes . ESGCT 27th Annual Congress in collaboration with SETGyc (pp.1). Barcelona, Spain

ERENDOR, FULYA Et Al. "LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes," ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 2019

ERENDOR, FULYA Et Al. "LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes." ESGCT 27th Annual Congress in collaboration with SETGyc , Barcelona, Spain, pp.1, 2019

ERENDOR, F. Et Al. (2019) . "LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes." ESGCT 27th Annual Congress in collaboration with SETGyc , Barcelona, Spain, p.1.

@conferencepaper{conferencepaper, author={FULYA ERENDOR Et Al. }, title={LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes}, congress name={ESGCT 27th Annual Congress in collaboration with SETGyc}, city={Barcelona}, country={Spain}, year={2019}, pages={1} }